Evidence map›Paper›PMID 35831019›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2022

PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma.

Wenliang Pan, Marc Scherlinger, Nobuya Yoshida, Maria G Tsokos, George C Tsokos

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Protein Phosphatase 2A Promotes CD8Research (Washington, D.C.) · 2025
    Article
  4. Protein phosphatases in systemic autoimmunity.Immunometabolism (Cobham, Surrey) · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Wenliang PanDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Marc ScherlingerDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-9453-5895
Nobuya YoshidaDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Maria G TsokosDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0001-8072-1358
George C TsokosDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA gtsokos@bidmc.harvard.edu.ORCID 0000-0001-9589-2360
Beth Israel Deaconess Medical Center · US

Funding

Phosphatases in Human LupusR01AI068787 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI TSOKOS, GEORGE C · 2007 to 2016
$4.1M
Phosphatases in Systemic AutoimmunityR01AI136924 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI TSOKOS, GEORGE C · 2018 to 2022
$2.2M
NIAID NIH HHS R01 AI068787NIAID NIH HHS R01 AI136924
6 · The paper itself

Abstract

We had shown previously that the protein phosphatase 2A regulatory subunit PPP2R2D suppresses IL-2 production, and PPP2R2D deficiency in T cells potentiates the suppressive function of regulatory T (Treg) cells and alleviates imiquimod-induced lupus-like pathology. In this study, in a melanoma xenograft model, we noted that the tumor grew in larger sizes in mice lacking PPP2R2D in T cells (Lck

Indexed as

MelanomaT-Lymphocytes, RegulatoryAnimalsCell ProliferationHumansInterleukin-2MiceProgrammed Cell Death 1 ReceptorProtein Phosphatase 2Interleukin-2PPP2R2D protein, humanPpp2r2d protein, mouseProgrammed Cell Death 1 ReceptorProtein Phosphatase 2

Identifiers

PMID35831019
PMCPMC9339485
OpenAlexW4285496097

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.